| Oct 29 |
AtriCure Non-GAAP EPS of -$0.17 beats by $0.03, revenue of $115.91M beats by $3.66M
|
| Oct 29 |
AtriCure Reports Third Quarter 2024 Financial Results
|
| Oct 28 |
AtriCure to Participate in the UBS Global Healthcare Conference
|
| Oct 16 |
AtriCure's Stock Rises After Launch of cryoSPHERE MAX Device
|
| Oct 15 |
AtriCure Announces Launch of cryoSPHERE MAX™ Probe for Post-Operative Pain Management
|
| Oct 13 |
Shareholders in AtriCure (NASDAQ:ATRC) are in the red if they invested three years ago
|
| Oct 11 |
AtriCure Gets CE Mark for EnCompass Clamp, Expands in Europe
|
| Oct 8 |
AtriCure to Announce Third Quarter 2024 Financial Results
|
| Oct 1 |
AtriCure Receives CE-Mark for the EnCompass® Clamp
|
| Sep 18 |
Here’s Why TimesSquare Capital U.S. Small Cap Growth Strategy Decided to Sell AtriCure (ATRC)
|
